Signal Transduction in Anaplastic Large Cell Lymphoma Cells (ALCL) Mediated by the Tumor Necrosis Factor Receptor CD30

Expression of the cytokine receptor CD30 is a characteristic feature of anaplastic large cell lymphoma (ALCL). Reports regarding CD30-mediated signaling in ALCL cells are highly controversial, especially with respect to the regulation of cell survival. In this study, we stimulated 6 ALCL-derived cell lines with immobilized anti-CD30 antibody. CD30-induced cell death was investigated by Western blot and FACS analysis. CD30-dependent cell proliferation and activation was analyzed by applying the trypan blue exclusion method and a luciferase-based ATP assay. The expression of cell cycle relevant proteins and the activation of mitogen-activated protein (MAP) kinases were also examined We demonstrated that activation of CD30 did not lead to the cleavage of pro-caspase-3. FACS analysis confirmed that in all examined cells cell death was not mediated by CD30. Cell growth was strongly inhibited in 2 of the 6 cell lines and restrained cell growth was accompanied by expression of the cell cycle inhibitor p21WAF1/CIP1. Furthermore, stimulation of CD30 led to the activation of the p38 MAP kinase but not of the extracellular signal-regulated kinase (ERK) or the jun N-terminal kinase (JNK). Interestingly, activation of CD30 induced a strong synergistic reduction of cell activity, if the p38 MAP kinase activity was blocked by SB203580. The aim of the study was to elucidate CD30-induced signaling in different ALCL-cells. Our results suggest that CD30-mediated apoptosis is not a common feature in this cell type and that p38 MAP kinase is involved in CD30-mediated singal transduction.

[1]  V. Diehl,et al.  Characterization of a Novel Human Anaplastic Large Cell Lymphoma Cell Line Tumorigenic in SCID Mice , 2002, Leukemia & lymphoma.

[2]  C. Schneider,et al.  Pleiotropic Signal Transduction Mediated by Human CD30: A Member of the Tumor Necrosis Factor Receptor (TNFR) Family , 2002, Leukemia & lymphoma.

[3]  S. Morris,et al.  Alk+ CD30+ lymphomas: a distinct molecular genetic subtype of non‐hodgkin's lymphoma , 2001, British journal of haematology.

[4]  E. Hildt,et al.  CD30-mediated cell cycle arrest associated with induced expression of p21CIP1/WAF1 in the anaplastic large cell lymphoma cell line Karpas 299 , 2001, Oncogene.

[5]  C. Duckett,et al.  Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. , 2000, Blood.

[6]  S. Pileri,et al.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. , 2000, Blood.

[7]  M. Kadin,et al.  Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: a possible mechanism for disease progression. , 2000, The Journal of investigative dermatology.

[8]  R. Junghans,et al.  Anti-CD30 antibody–based therapy , 2000, Current opinion in oncology.

[9]  L. Boise,et al.  CD30 Signals Integrate Expression of Cytotoxic Effector Molecules, Lymphocyte Trafficking Signals, and Signals for Proliferation and Apoptosis1 , 2000, The Journal of Immunology.

[10]  M. Werner,et al.  Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas , 2000, Leukemia.

[11]  J. Inoue,et al.  TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, and TRAF3 and Activates NF-κB, Elk-1, c-Jun N-Terminal Kinase, and p38 Mitogen-Activated Protein Kinase1 , 2000, The Journal of Immunology.

[12]  S. Hsu,et al.  Autocrine Growth Regulation of CD30 Ligand in CD30-Expressing Reed-Sternberg Cells: Distinction Between Hodgkin's Disease and Anaplastic Large Cell Lymphoma , 2000, Laboratory Investigation.

[13]  G. Cheng,et al.  Membrane Localization of TRAF 3 Enables JNK Activation* , 2000, The Journal of Biological Chemistry.

[14]  I. Scheffrahn,et al.  The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation. , 1999, Experimental hematology.

[15]  M. Kadin,et al.  A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1). , 1999, The American journal of pathology.

[16]  Peter Scheurich,et al.  Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF‐R1 activation by endogenous membrane‐anchored TNF , 1999, The EMBO journal.

[17]  G. Inghirami,et al.  CD30 in normal and neoplastic cells. , 1999, Clinical immunology.

[18]  H. Nakano,et al.  Differential regulation of IκB kinase α and β by two upstream kinases, NF-κB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1 , 1998 .

[19]  H. Nakano,et al.  Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  I. Herr,et al.  Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.

[21]  D. Longo,et al.  In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. , 1995, Cancer research.

[22]  G. Pizzolo,et al.  CD30 ligation induces nuclear factor‐ϰB activation in human T cell lines , 1995, European journal of immunology.

[23]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[24]  N. Copeland,et al.  CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF , 1993, Cell.

[25]  H. Stein,et al.  Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease , 1992, Cell.

[26]  K. Lennert,et al.  Updated Kiel classification for lymphomas , 1989, The Journal of pathology.